Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00716898
Recruitment Status : Completed
First Posted : July 16, 2008
Last Update Posted : April 15, 2016
Sponsor:
Information provided by (Responsible Party):
yair plesser, Shaare Zedek Medical Center

Brief Summary:
The purpose of the study is to determine the Pharmacokinetics of Low Molecular Weight Heparin (LMWH) in Cancer patients, and compare it to the Pharmacokinetics of LMWH in Patients without cancer. We also intend to detect any correlation between heparanase blood and urine levels and the Pharmacokinetics of LMWH.

Condition or disease
Cancer Thrombosis Angina Pectoris

Show Show detailed description

Layout table for study information
Study Type : Observational
Actual Enrollment : 25 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients Compared to Patients With Unstable Angina Pectoris; The Possible Role of Heparanase
Study Start Date : February 2009
Actual Primary Completion Date : June 2011
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Heparin

Group/Cohort
1

A. Patients with pathologically or cytologically confirmed diagnosis of advanced solid malignancy.

B. Venous thromboembolism: Deep vein thrombosis (DVT) confirmed by Doppler ultrasound, or pulmonary embolism confirmed by lung ventilation perfusion scan, or computerized tomography.

C. Treatment with therapeutic dose of low molecular weight heparin. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. Serum creatinine level < 1.5 mg/dl. G. Informed consent

2

A. Patients with unstable angina pectoris/ atypical chest pain, with no evidence of acute myocardial infarction.

B. Treatment with therapeutic dose of low molecular weight heparin. C. No evidence of VTE. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. No history of malignancy. G. Serum creatinine level < 1.5 mg/dl. H. Informed consent




Primary Outcome Measures :
  1. Pharmacokinetics of Low Molecular Weight Heparin (LMWH) in Cancer patients [ Time Frame: Interim analysis and at the end of the trial ]

Secondary Outcome Measures :
  1. The role of heparanase on the Pharmacokinetics of Low Molecular Weight Heparin (LMWH) in Cancer patients [ Time Frame: End of the study ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients treated at SZMC
Criteria

Inclusion Criteria:

  • Treatment with therapeutic dose of low molecular weight heparin
  • Serum creatinine level < 1.5 mg/dl.

Exclusion Criteria:

  • major surgery during the last month before investigation
  • evidence of major infectious disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00716898


Locations
Layout table for location information
Israel
Shaare Zedek Medicla Center
Jerusalm, Israel, 91031
Sponsors and Collaborators
Shaare Zedek Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Nicola j nasser, MD, PhD Shaare Zedek MC
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: yair plesser, study manager, Shaare Zedek Medical Center
ClinicalTrials.gov Identifier: NCT00716898    
Other Study ID Numbers: Nasser-2008-1CTIL
First Posted: July 16, 2008    Key Record Dates
Last Update Posted: April 15, 2016
Last Verified: April 2016
Keywords provided by yair plesser, Shaare Zedek Medical Center:
Condition
Cancer
Patients
Thrombosis
Unstable
Angina
Pectoris
Additional relevant MeSH terms:
Layout table for MeSH terms
Thrombosis
Angina Pectoris
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Myocardial Ischemia
Heart Diseases
Chest Pain
Pain
Neurologic Manifestations
Signs and Symptoms